![Hypersensitivity Reactions to Taxanes and Subsequent Treatment with Nab- Paclitaxel: Case Reports of 2 Women with Early-Stage Breast Cancer Hypersensitivity Reactions to Taxanes and Subsequent Treatment with Nab- Paclitaxel: Case Reports of 2 Women with Early-Stage Breast Cancer](https://jhoponline.com/images/jhop/2021/December/Hypersensitivity-Reactions-Figure1.jpg)
Hypersensitivity Reactions to Taxanes and Subsequent Treatment with Nab- Paclitaxel: Case Reports of 2 Women with Early-Stage Breast Cancer
![PDF] Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer | Semantic Scholar PDF] Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/2b8243d0cd6da82dad4e6b60a9fd68978010e599/10-Table5-1.png)
PDF] Safety and Efficacy of nab-Paclitaxel in the Treatment of Patients with Breast Cancer | Semantic Scholar
![Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer - Tamura - 2017 - Cancer Science - Wiley Online Library Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer - Tamura - 2017 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/220eae14-4029-46e6-931a-bd797d6eeedf/cas13221-toc-0001-m.jpg?trick=1701634715541)
Randomized phase II study of nab‐paclitaxel as first‐line chemotherapy in patients with HER2‐negative metastatic breast cancer - Tamura - 2017 - Cancer Science - Wiley Online Library
![NEJM on X: "#VisualAbstract: Aezolizumab + nab-paclitaxel as first-line therapy for patients with advanced or metastatic triple-negative #breastcancer significantly prolonged progression-free survival, particularly among those with PD-L1–positive ... NEJM on X: "#VisualAbstract: Aezolizumab + nab-paclitaxel as first-line therapy for patients with advanced or metastatic triple-negative #breastcancer significantly prolonged progression-free survival, particularly among those with PD-L1–positive ...](https://pbs.twimg.com/media/DtMiuSQW0AA2KQB.jpg)
NEJM on X: "#VisualAbstract: Aezolizumab + nab-paclitaxel as first-line therapy for patients with advanced or metastatic triple-negative #breastcancer significantly prolonged progression-free survival, particularly among those with PD-L1–positive ...
![Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model | Cell Death Discovery Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model | Cell Death Discovery](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41420-023-01397-y/MediaObjects/41420_2023_1397_Fig1_HTML.png)
Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRASG12D mutated pancreatic cancer in vivo model | Cell Death Discovery
![Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial - The Lancet Gastroenterology & Hepatology Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/2091737319/2076224900/gr1.gif)
Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial - The Lancet Gastroenterology & Hepatology
![Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients | Advances in Therapy Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients | Advances in Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs12325-019-01058-6/MediaObjects/12325_2019_1058_Fig1_HTML.png)
Pharmacokinetics of Total and Unbound Paclitaxel After Administration of Paclitaxel Micellar or Nab-Paclitaxel: An Open, Randomized, Cross-Over, Explorative Study in Breast Cancer Patients | Advances in Therapy
![Paclitaxel vs Abraxane (albumin-bound paclitaxel) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group Paclitaxel vs Abraxane (albumin-bound paclitaxel) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group](https://i0.wp.com/pharmaceuticalintelligence.com/wp-content/uploads/2020/07/paclitaxel-vs-abraxane-albumin-bound-paclitaxel.png?resize=500%2C310&ssl=1)
Paclitaxel vs Abraxane (albumin-bound paclitaxel) | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial - Annals of Oncology
![Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II ... Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II ...](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-020-07047-1/MediaObjects/12885_2020_7047_Fig1_HTML.png)
Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II ...
![Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety](https://www.mdpi.com/biomedicines/biomedicines-11-02000/article_deploy/html/images/biomedicines-11-02000-g003.png)
Biomedicines | Free Full-Text | Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety
![Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer? | Journal of Clinical Oncology Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer? | Journal of Clinical Oncology](https://ascopubs.org/cms/10.1200/JCO.19.00877/asset/images/large/jco.19.00877t2.jpeg)
Nab-Paclitaxel: A New Standard of Care in Neoadjuvant Therapy of High-Risk Early Breast Cancer? | Journal of Clinical Oncology
![Chemical structure of Paclitaxel and the albumin conjugated variant... | Download Scientific Diagram Chemical structure of Paclitaxel and the albumin conjugated variant... | Download Scientific Diagram](https://www.researchgate.net/publication/353277452/figure/fig2/AS:1046004384161801@1626398287917/Chemical-structure-of-Paclitaxel-and-the-albumin-conjugated-variant-Nab-Paclitaxel.png)
Chemical structure of Paclitaxel and the albumin conjugated variant... | Download Scientific Diagram
![Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives - ScienceDirect Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0305737216300834-gr1.jpg)
Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives - ScienceDirect
![Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis | BMC Cancer | Full Text Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis | BMC Cancer | Full Text](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs12885-021-07831-7/MediaObjects/12885_2021_7831_Fig2_HTML.png)
Comparison between nab-paclitaxel and solvent-based taxanes as neoadjuvant therapy in breast cancer: a systematic review and meta-analysis | BMC Cancer | Full Text
![Updates of Key Studies Differ on Relative Benefit of Nab-Paclitaxel in Breast Cancer - The ASCO Post Updates of Key Studies Differ on Relative Benefit of Nab-Paclitaxel in Breast Cancer - The ASCO Post](https://ascopost.com/media/14007219/35_table.jpg)